flurbiprofen and omeprazole

flurbiprofen has been researched along with omeprazole in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (25.00)29.6817
2010's12 (60.00)24.3611
2020's3 (15.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM1
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL1
Cherkaoui, S; Daali, Y; Dayer, P; Jerdi, MC; Oestreicher, MK1
Collins, DA; Deng, Y; Jenkins, J; Kitchen, VS; Williams, D1
Bosilkovska, M; Daali, Y; Déglon, J; Desmeules, J; Samer, C; Staub, C; Walder, B1
Bosilkovska, M; Daali, Y; Dayer, P; Déglon, J; Desmeules, JA; Rebsamen, M; Samer, CF; Staub, C; Walder, B1
Matsumoto, Y; Matsushita, A; Murayama, N; Shukuya, M; Uno, Y; Yamazaki, H1
Inoue, T; Kawano, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H1
Lutz, WK; Schönfelder, G; Steinfath, M; Vogl, S1
Bosilkovska, M; Daali, Y; Déglon, J; Desmeules, J; Samer, C; Thomas, A; Walder, B1
Camacho-Muñoz, D; Kasprzyk-Hordern, B; Thomas, KV1
Brantley, SJ; Dai, X; Goulet, MT; Hard, ML; Hitron, M; Karol, MD; McLaughlin, CF1
Bachmann, F; Bouitbir, J; Duthaler, U; Grandinetti, T; Haschke, M; Hruz, P; Krähenbühl, S; Pfefferkorn, F; Suenderhauf, C1
Berger, B; Berse, M; Dingemanse, J; Grignaschi, N; Kaufmann, P; Treiber, A1

Reviews

1 review(s) available for flurbiprofen and omeprazole

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

2 trial(s) available for flurbiprofen and omeprazole

ArticleYear
Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
    Basic & clinical pharmacology & toxicology, 2016, Volume: 119, Issue:3

    Topics: Adolescent; Adult; Bupropion; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Dose-Response Relationship, Drug; Dried Blood Spot Testing; Drug Interactions; Female; Flurbiprofen; Genotyping Techniques; Humans; Male; Midazolam; Omeprazole; Phenotype; Terfenadine; Young Adult

2016
Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
    Clinical pharmacology in drug development, 2021, Volume: 10, Issue:8

    Topics: Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzofurans; Bupropion; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Flurbiprofen; Gene Expression Regulation; Half-Life; Healthy Volunteers; Humans; Male; Midazolam; Naphthoquinones; Neoplasm Proteins; Omeprazole; Rosuvastatin Calcium; Young Adult

2021

Other Studies

17 other study(ies) available for flurbiprofen and omeprazole

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
    Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship

2008
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:11

    Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat

2016
A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes.
    Journal of pharmaceutical and biomedical analysis, 2004, Sep-03, Volume: 35, Issue:5

    Topics: Biotransformation; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Flurbiprofen; Humans; Isoenzymes; Midazolam; Omeprazole; Phenotype; Reproducibility of Results; Sensitivity and Specificity

2004
Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
    European journal of clinical pharmacology, 2010, Volume: 66, Issue:1

    Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoates; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Flurbiprofen; Humans; Hydrazines; Isoenzymes; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Pyrazoles; Receptors, Thrombopoietin

2010
Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma.
    Bioanalysis, 2014, Volume: 6, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bupropion; Caffeine; Calibration; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Dried Blood Spot Testing; Flurbiprofen; Half-Life; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine

2014
Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.
    Clinical pharmacology and therapeutics, 2014, Volume: 96, Issue:3

    Topics: Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bupropion; Caffeine; Capsules; Carbonated Beverages; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Coffee; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Dried Blood Spot Testing; Enzyme Inhibitors; Feasibility Studies; Flurbiprofen; Humans; Isoenzymes; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Phenotype; Pilot Projects; Predictive Value of Tests; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine; Young Adult

2014
CYP2C19 polymorphisms account for inter-individual variability of drug metabolism in cynomolgus macaques.
    Biochemical pharmacology, 2014, Sep-15, Volume: 91, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Flurbiprofen; Gene Expression Regulation, Enzymologic; Macaca fascicularis; Macaca mulatta; Microsomes, Liver; Models, Molecular; Omeprazole; Polymorphism, Genetic; Protein Conformation; Proton Pump Inhibitors; Warfarin

2014
Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates, S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole.
    Drug metabolism and disposition: the biological fate of chemicals, 2015, Volume: 43, Issue:10

    Topics: Amino Acid Sequence; Animals; Callithrix; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Female; Flurbiprofen; Humans; Macaca fascicularis; Male; Microsomes, Liver; Molecular Sequence Data; Omeprazole; Phylogeny; Species Specificity; Substrate Specificity; Tolbutamide; Warfarin

2015
Effect of Omeprazole and Dextromethorphan on the Urinary Metabolic Ratio of Flurbiprofen.
    Basic & clinical pharmacology & toxicology, 2016, Volume: 118, Issue:6

    Topics: Adult; Cytochrome P450 Family 2; Dextromethorphan; Drug Interactions; Female; Flurbiprofen; Germany; Healthy Volunteers; Humans; Male; Omeprazole; Polymorphism, Single Nucleotide; Young Adult

2016
Enantioselective simultaneous analysis of selected pharmaceuticals in environmental samples by ultrahigh performance supercritical fluid based chromatography tandem mass spectrometry.
    Analytica chimica acta, 2016, Aug-31, Volume: 934

    Topics: Aminorex; Carbazoles; Chloramphenicol; Chromatography, High Pressure Liquid; Chromatography, Supercritical Fluid; Flurbiprofen; Humans; Ibuprofen; Ifosfamide; Imidazoles; Indoprofen; Molecular Structure; Naproxen; Ofloxacin; Omeprazole; Praziquantel; Solid Phase Extraction; Stereoisomerism; Tandem Mass Spectrometry; Tetramisole; Water Pollutants, Chemical

2016
Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.
    Clinical pharmacokinetics, 2022, Volume: 61, Issue:7

    Topics: Caffeine; Child; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Flurbiprofen; Humans; Liver Cirrhosis; Metoprolol; Midazolam; Omeprazole

2022
Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects.
    Pharmacology research & perspectives, 2023, Volume: 11, Issue:5

    Topics: Adult; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Flurbiprofen; Healthy Volunteers; Humans; Midazolam; Omeprazole; Orexins

2023